BMRN
BioMarin Pharmaceutical Inc.
NASDAQ · Healthcare · Biotechnology · US
$66.35
−0.12%Aug 31, 2026, 11:05 UTC
BioMarin Pharmaceutical signed a binding term sheet with Ascendis Pharma for a global settlement and license agreement, granting Ascendis a non-exclusive, worldwide, royalty-bearing license to certain BioMarin patents for products including TransCon CNP, navepegritide, or Yuviwel, with all pending litigation to be dismissed with prejudice.
Source:Aug 18, 2026, 00:00 UTC
BioMarin Pharmaceutical Inc. agreed to acquire Alesta Therapeutics B.V. in a cash-free, debt-free share purchase transaction for an upfront $275 million cash payment plus up to $215 million in contingent development milestone payments, with closing expected in the third quarter of 2026.
Aug 12, 2026, 14:05 UTC
BioMarin Pharmaceutical announced plans to integrate Amicus Therapeutics as part of its rare-disease growth strategy, with a focus on faster deleveraging.
Source:Aug 6, 2026, 20:03 UTC
BioMarin reported second quarter 2026 financial results with total revenues of $990 million, up 20% year-over-year.
Jul 27, 2026, 13:05 UTC
BioMarin and n-Lorem Foundation entered a strategic collaboration and global exclusive license agreement to develop an antisense oligonucleotide medicine for ReNU syndrome.
Source:Jul 14, 2026, 15:46 UTC
The FDA accepted BioMarin's supplemental New Drug Application seeking full approval for Voxzogo in achondroplasia.
Source:Jun 4, 2026, 00:00 UTC
BioMarin Pharmaceutical Inc. elected Elizabeth M. Anderson, Barbara W. Bodem, Ian T. Clark, Athena Countouriotis, and Willard Dere as directors, effective June 2, 2026.